Skip to main content
. Author manuscript; available in PMC: 2021 Dec 10.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 5;47(5):1168–1182. doi: 10.1007/s00259-019-04625-9

Fig 4. Radiomics signatures of NSCLC patients.

Fig 4.

(a~b) The CT, PET, and fusion images for a patient with ADC NSCLC obtained 1 month before and 6 month after immunotherapy, which means the patient would have DCB since the start of immunotherapy and 6 month post immunotherapy; (c)~(d) The CT, PET, and fusion images for a patient with ADC NSCLC obtained 1 month before and 9 month after immunotherapy, which means the patient would have DCB since the start of immunotherapy, but would have NDB after 9 month immunotherapy. The corresponding clinical feature and radiomics scores are shown in the bottom of each image.